ASCO活指南2026.3.2版:驱动基因突变IV期非小细胞肺癌治疗
该活指南由ASCO常设专家小组持续系统审查文献并定期更新,针对驱动基因突变IV期非小细胞肺癌的治疗推荐。本版本未在摘要中报告具体推荐条款与数值,临床决策需结合完整指南正文及患者个体情况。
要点
- ASCO活指南针对驱动基因突变IV期NSCLC治疗定期更新
- 推荐基于常设专家小组持续系统文献审查
- 本摘要未提供具体推荐条款与疗效数值
核心结论
- ASCO活指南为驱动基因突变IV期非小细胞肺癌治疗提供定期更新的推荐,具体推荐内容需参见指南正文。
研究设计与样本
- 由ASCO常设专家小组按ASCO指南方法学手册持续系统审查健康文献并定期更新。
- 遵循ASCO临床实践指南利益冲突政策实施流程。
临床怎么用
- 临床使用时需查阅ASCO完整指南正文获取具体推荐条款。
- 活指南不替代治疗临床医生的独立专业判断,也不考虑患者个体差异。
局限性
- 摘要未报告具体推荐、疗效数值及证据等级。
- 活指南不替代独立专业判断且未考虑患者个体差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
[Box: see text]Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2, online only). Updates are published regularly and can be found on the ASCO Publications website.
引用
- Puri S, Ismaila N, Azar IH, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2. J Clin Oncol. 2026. PMID: 42372216. doi:10.1200/JCO-26-01479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。